- Tags: glaucoma
Products
VEO Ophthalmics and PeriVision launch VisionOne AI VF platform in the US
Exclusive partnership enables commercial market availability of the portable novel perimeter device, designed to perform visual field testing for glaucoma.
Products
Lumenis unveils updates to Digital Duet SLT+YAG platform
Version 2.0 builds on the advancements of the first and only all-in-one digital dual path system of its kind on the market.
Research
Physical activity tied to decreased glaucoma progression
Study highlights several ways that exercise may reduce the risk of progression in POAG patients.
Pipeline
FDA grants IDE approval for Avisi's glaucoma treatment device
IDE approval enables initiation of the open-label SAPPHIRE to evaluate the VisiPlate, an aqueous shunt designed to lower IOP among OAG patients.
Products
Iantrek launches AlloFlow Uveo in the US
Bio-interventional surgical implant targets the uveoscleral pathway to enhance aqueous flow (and lower IOP) in glaucoma patients.
Research
Childhood BMI may determine risk for POAG development
Regardless of childhood weight, low body size in adulthood consistently served as a risk factor for POAG.
Products
FDA approves FDC Limited's pilocarpine HCl ophthalmic solution
ANDA approval for generic eye drop extends to three concentrations: 1%, 2%, and 4%.
Products
FDA approves Amneal's bimatoprost 0.01% generic
Generic version of Allergan’s LUMIGAN is indicated for reducing elevated IOP in glaucoma and ocular hypertensive patients.
Research
Potential glaucoma prevention benefits linked to nitrate use
Oral nitrate use in patients with ischemic heart disease may have protective effects against glaucoma development.
Products
Sagent launches travoprost 0.004% generic for IOP reduction
Generic version of Novartis’s TRAVATAN Z is intended as a first-line treatment for patients with open-angle glaucoma and ocular hypertension.
Research
Glaucoma Research Foundation receives $5M gift to launch initiative
The Treatment Accelerator Initiative is designed to fund and accelerate the preclinical to phase 1 stage of potential therapeutics for optic nerve preservation.
Research
Researchers identify long-term risk factors of VF progression in glaucoma
Study outlines key considerations for treating patients with primary angle-closure disease.
Pipeline
Nicox reports positive phase 3 data on NCX 470 glaucoma eye drop
Topline results from the Denali trial support a future NDA submission for the nitric oxide-donating bimatoprost formulation to lower IOP.
Products
New World Medical debuts new Ahmed ClearPath glaucoma device
Latest model of the non-valved glaucoma drainage device for IOP reduction features a smaller tube lumen, offering surgeons more options and flexibility.
Research
Are prostaglandins really the most effective glaucoma therapy?
Prostaglandin analogs were most effective when used in combination with other topical medications.Products
Iantrek raises $42M for launch of uveoscleral pathway glaucoma tech
AlloFlo Uveo is a hardware-free, naturally-derived bio-tissue solution for lowering IOP in POAG patients; commercial launch planned for later this year.
Research
How successful are pediatric glaucoma procedures?
Study identifies high failure rate and key factors associated with likelihood of failure.
Pipeline
FDA green lights Myra Vision's IDE study for glaucoma
IDE approval enables company to initiate the open-label ADAPT study on its proprietary Calibreye TGT Surgical System.
Events
Eyes On Glaucoma 2025 highlights advancements in disease care
Largest virtual glaucoma meeting of the year sees record attendance.
Research